Eyal Lifschitz is an entrepreneur and investor with years of experience in establishing and managing life science companies and their business development efforts.
Lifschitz serves as the Co-founder and Managing General Partner of Peregrine Ventures, a global life science venture capital fund dedicated to improving patients’ quality of life by investing in and supporting life changing healthcare opportunities. In this role, he oversees all daily operations and mentors entrepreneurs on their journeys to bring innovative medical technologies to market.
On behalf of Peregrine, Lifschitz serves on the boards of Memic Innovative Surgery, Ribon Therapeutics, CardioValve, Nectin Therapeutics, Restore Medical, Kahr, Cordio Medical, Raziel Therapeutics and others.
Previously, Lifschitz was involved as a founder and a manager in PharmaSys (acquired by Elan Corp. NYSE: ELN), ECR (acquired by AVX Corp. NYSE: AVX), Visioncare Ophthalmic Technologies, BioControl, and as a director of Given Imaging (NASDAQ: GIVN).
Lifschitz serves as Chairman in the Israeli Early-Stage Investors Association (IEI) & Technology Incubator Forum (ITIF) which promotes Israeli high-tech ventures both domestically and abroad. Lifschitz is also a Founder and Chairman of GamVeGam, a non-for-profit cooperation between the Israeli Ministry of Education and the Israeli high-tech industry which aims to encourage high-tech professionals to become teachers in public schools.
He holds an LLB from the Academic Center for Law and Science.